Immunovant Inc Market Cap ($6.00 Billion)
Market Cap & Net Worth: Immunovant Inc (IMVT)
Immunovant Inc market cap. Immunovant Inc (NASDAQ:IMVT) has a market capitalization of $6.00 Billion ($6.00 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3064 globally and #1109 in its home market, demonstrating a 3.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunovant Inc's stock price $29.04 by its total outstanding shares 206552682 (206.55 Million). Also see IMVT cash generation efficiency for how efficiently the company converts equity into cash flow.
Immunovant Inc Market Cap History (2019–2026)
Immunovant Inc market cap history from 2019 to 2026. Data shows growth from $3.28 Billion to $6.00 Billion (15.63% CAGR). Check IMVT live share price for real-time trading data and today's change.
Index Memberships
Immunovant Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.23% | #75 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.01% | #344 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.33% | #52 of 263 |
Weight: Immunovant Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunovant Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunovant Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IMVT net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IMVT by Market Capitalization
Companies near Immunovant Inc in the global market cap rankings as of November 4, 2026. Also see IMVT asset base for a full breakdown of the balance sheet.
Key companies related to Immunovant Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Immunovant Inc (2019–2026)
Market capitalization of Immunovant Inc from 2019 to today. Between 2019 and today, Immunovant Inc's market cap moved from $3.28 Billion to $ 6.00 Billion, with a yearly change of 15.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.00 Billion | +14.24% |
| 2025 | $5.25 Billion | +2.62% |
| 2024 | $5.12 Billion | -41.21% |
| 2023 | $8.70 Billion | +137.35% |
| 2022 | $3.67 Billion | +108.33% |
| 2021 | $1.76 Billion | -81.55% |
| 2020 | $9.54 Billion | +191.05% |
| 2019 | $3.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Immunovant Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.00 Billion USD |
| MoneyControl | $6.00 Billion USD |
| MarketWatch | $6.00 Billion USD |
| marketcap.company | $6.00 Billion USD |
| Reuters | $6.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinat… Read more